Ningling Ge

2.1k total citations · 1 hit paper
44 papers, 1.4k citations indexed

About

Ningling Ge is a scholar working on Hepatology, Oncology and Cancer Research. According to data from OpenAlex, Ningling Ge has authored 44 papers receiving a total of 1.4k indexed citations (citations by other indexed papers that have themselves been cited), including 24 papers in Hepatology, 22 papers in Oncology and 12 papers in Cancer Research. Recurrent topics in Ningling Ge's work include Hepatocellular Carcinoma Treatment and Prognosis (24 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Liver Disease Diagnosis and Treatment (7 papers). Ningling Ge is often cited by papers focused on Hepatocellular Carcinoma Treatment and Prognosis (24 papers), Cancer Immunotherapy and Biomarkers (9 papers) and Liver Disease Diagnosis and Treatment (7 papers). Ningling Ge collaborates with scholars based in China, United States and India. Ningling Ge's co-authors include Zhenggang Ren, Sheng‐Long Ye, Jia Fan, Yanhong Wang, Lan Zhang, Tong‐Chun Xue, Boheng Zhang, Hui‐Chuan Sun, Jianhua Yang and Songbin Fu and has published in prestigious journals such as Journal of Biological Chemistry, Journal of Clinical Oncology and PLoS ONE.

In The Last Decade

Ningling Ge

42 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Downstaging and Resection of Initially Unresectable Hepatocellular Carcinoma with Tyrosine Kinase Inhibitor and Anti-PD-1 Antibody Combinations

2021 159 citations Xiao‐Dong Zhu, Cheng Huang et al. profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Ningling Ge China	20	708	505	411	328	323	44	1.4k
Hanako Tsujikawa Japan	15	466 0.7×	403 0.8×	262 0.6×	333 1.0×	334 1.0×	37	1.2k
Aurélie Hérault France	12	433 0.6×	337 0.7×	394 1.0×	253 0.8×	808 2.5×	15	1.7k
Ze‐Ya Pan China	23	1.2k 1.7×	478 0.9×	449 1.1×	728 2.2×	486 1.5×	55	2.1k
Stefania Brozzetti Italy	21	337 0.5×	468 0.9×	393 1.0×	343 1.0×	586 1.8×	50	1.6k
Shunjun Fu China	17	421 0.6×	607 1.2×	395 1.0×	285 0.9×	360 1.1×	48	1.2k
Lijian Liang China	23	407 0.6×	489 1.0×	325 0.8×	262 0.8×	529 1.6×	74	1.4k
Xinyu Bi China	17	400 0.6×	480 1.0×	245 0.6×	216 0.7×	361 1.1×	100	1.2k
Tai Hato Japan	16	362 0.5×	822 1.6×	379 0.9×	169 0.5×	435 1.3×	38	1.8k
Goro Watanabe Japan	19	837 1.2×	552 1.1×	444 1.1×	480 1.5×	502 1.6×	92	2.1k
Yong Yi China	27	347 0.5×	905 1.8×	474 1.2×	285 0.9×	607 1.9×	68	2.0k

Countries citing papers authored by Ningling Ge

Since Specialization

Citations

This map shows the geographic impact of Ningling Ge's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ningling Ge with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ningling Ge more than expected).

Fields of papers citing papers by Ningling Ge

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ningling Ge. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ningling Ge. The network helps show where Ningling Ge may publish in the future.

Co-authorship network of co-authors of Ningling Ge

This figure shows the co-authorship network connecting the top 25 collaborators of Ningling Ge. A scholar is included among the top collaborators of Ningling Ge based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ningling Ge. Ningling Ge is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Zhang, Juan, Xiaojian Ni, Youpei Lin, et al.. (2025). AGEs-RAGE manipulates tumor intrinsic pERK/Sp1/IL6 pathway and reprograms macrophage to promote intrahepatic cholangiocarcinoma progression. Translational Oncology. 60. 102446–102446.

Li, Jie, Li Song, Xingxing Zhang, et al.. (2025). Survival in patients with unresectable hepatocellular carcinoma: TCC cocktail plus TACE vs TACE alone prospective randomized clinical trial. Journal of Translational Medicine. 23(1). 812–812.

Xu, Xin, Xiaojian Ni, Jiaomeng Pan, et al.. (2023). Gene-based cancer-testis antigens as prognostic indicators in hepatocellular carcinoma. Heliyon. 9(3). e13269–e13269. 3 indexed citations

Hsu, Shu-Jung, Xin Xu, Maopei Chen, et al.. (2021). Hepatic Arterial Infusion Chemotherapy with Modified FOLFOX as an Alternative Treatment Option in Advanced Hepatocellular Carcinoma Patients with Failed or Unsuitability for Transarterial Chemoembolization. Academic Radiology. 28. S157–S166. 22 indexed citations

Huang, Cheng, Xiao‐Dong Zhu, Ying‐Hao Shen, et al.. (2021). Organ specific responses to first-line lenvatinib plus anti-PD-1 antibodies in patients with unresectable hepatocellular carcinoma: a retrospective analysis. Biomarker Research. 9(1). 19–19. 48 indexed citations

Jiang, He, Feifei Yuan, Zhiying Zhao, et al.. (2021). Expression and Clinical Significance of MPS-1 in Hepatocellular Carcinoma. International Journal of General Medicine. Volume 14. 9145–9152. 2 indexed citations

Zhang, Lan, Yanhong Wang, Ningling Ge, et al.. (2021). When will it be better? Lenvatinib combined with TACE for unresectable hepatocellular carcinoma: A retrospective analysis of real-world evidence in China.. Journal of Clinical Oncology. 39(3_suppl). 281–281. 2 indexed citations

Zhang, Lan, Yanhong Wang, Ningling Ge, et al.. (2021). The dose-optimisation of lenvatinb for patients with unresectable hepatocellular carcinoma in clinical practice: A retrospective analysis of real-world evidence in China.. Journal of Clinical Oncology. 39(3_suppl). 280–280. 2 indexed citations

Li, Jinghuan, Xin Yin, Wenshuai Fan, et al.. (2021). Development of a Prognostic Scoring System for Hepatocellular Carcinoma Patients With Main Portal Vein Tumor Thrombus Undergoing Conventional Transarterial Chemoembolization: An Analysis of 173 Patients. Frontiers in Oncology. 11. 671171–671171. 6 indexed citations

10.

Chen, Rongxin, Yuhong Gan, Ningling Ge, et al.. (2019). A new prediction model for prognosis of patients with intermediate-stage HCC after conventional transarterial chemoembolization: an internally validated study. Journal of Cancer. 10(26). 6535–6542. 5 indexed citations

11.

Wang, Zheng, Zhenggang Ren, Yi Chen, et al.. (2018). Adjuvant Transarterial Chemoembolization for HBV-Related Hepatocellular Carcinoma After Resection: A Randomized Controlled Study. Clinical Cancer Research. 24(9). 2074–2081. 204 indexed citations

12.

Chen, Yi, Jia Fan, Zheng Wang, et al.. (2017). Clinical effect and prognostic factors analysis of intraoperative radiofrequency ablation in treatment of hepatocellular carcinoma with severe cirrhosis. Zhōnghuá xiāohuà wàikē zázhì/Zhonghua xiaohua waike zazhi. 16(2). 159–163. 1 indexed citations

13.

Xue, Tong‐Chun, Fan Le, Rongxin Chen, et al.. (2015). Transarterial chemoembolization for huge hepatocellular carcinoma with diameter over ten centimeters: a large cohort study. Medical Oncology. 32(3). 64–64. 44 indexed citations

14.

Xue, Tong‐Chun, Qingan Jia, Ningling Ge, et al.. (2015). Imbalance in systemic inflammation and immune response following transarterial chemoembolization potentially increases metastatic risk in huge hepatocellular carcinoma. Tumor Biology. 36(11). 8797–8803. 21 indexed citations

15.

Xue, Tong‐Chun, Qingan Jia, Ningling Ge, et al.. (2015). The platelet-to-lymphocyte ratio predicts poor survival in patients with huge hepatocellular carcinoma that received transarterial chemoembolization. Tumor Biology. 36(8). 6045–6051. 40 indexed citations

16.

Tang, Wenqing, Xuemei Feng, Si Zhang, et al.. (2015). Caveolin-1 Confers Resistance of Hepatoma Cells to Anoikis by Activating IGF-1 Pathway. Cellular Physiology and Biochemistry. 36(3). 1223–1236. 44 indexed citations

17.

Xue, Tong‐Chun, Lan Zhang, Ningling Ge, et al.. (2014). Prognostic Significance of the Neutrophil-to-Lymphocyte Ratio in Primary Liver Cancer: A Meta-Analysis. PLoS ONE. 9(5). e96072–e96072. 102 indexed citations

18.

Xue, Tong‐Chun, Ningling Ge, Lan Zhang, et al.. (2014). Goosecoid Promotes the Metastasis of Hepatocellular Carcinoma by Modulating the Epithelial-Mesenchymal Transition. PLoS ONE. 9(10). e109695–e109695. 26 indexed citations

19.

Shang, Xiaoying, Susan M. Burlingame, M. Fatih Okcu, et al.. (2009). Aurora A is a negative prognostic factor and a new therapeutic target in human neuroblastoma. Molecular Cancer Therapeutics. 8(8). 2461–2469. 79 indexed citations

20.

Vasudevan, Sanjeev A., Ningling Ge, Heidi V. Russell, et al.. (2009). Neuroblastoma-derived secretory protein is a novel secreted factor overexpressed in neuroblastoma. Molecular Cancer Therapeutics. 8(8). 2478–2489. 10 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact